PMID- 33639633
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1735-5249 (Electronic)
IS  - 1735-1502 (Linking)
VI  - 20
IP  - 1
DP  - 2021 Feb 11
TI  - Clinical Relevance of HLA-DRB1 and -DQB1 Alleles in Iranian Systemic Lupus 
      Erythematosus Patients.
PG  - 67-75
LID - 10.18502/ijaai.v20i1.5413 [doi]
AB  - Given the potential link between genetic risk factors and clinical features of 
      systemic lupus erythematosus (SLE), this study aimed to explore the relationship 
      between human leukocyte antigen (HLA)-DRB1/DQB1 alleles and haplotypes and 
      clinical sub-phenotypes of the disease in a group of Iranian SLE patients. 
      HLA-DRB1 and HLA-DQB1 alleles were determined by PCR-SSP in 127 SLE patients and 
      153 ethnically-matched healthy controls. The relationships between various 
      clinical manifestations and HLA alleles/haplotypes were analyzed in the patients. 
      We observed the positive associations of DRB1*07 and DRB1*07-DQB1*02 haplotypes 
      with articular and pulmonary involvement (p=0.006 and p<0.001 respectively), 
      DRB1*03 and DQB1*02 alleles, and DRB1*03-DQB1*02 haplotypes with cutaneous 
      (p=0.03, p=0.004 and p=0.02 respectively) and renal involvement, and DRB1*13 as 
      well as DRB1*13-DQB1*06 haplotypes with renal involvement. Conversely, negative 
      associations of DRB1*13 with cutaneous and gastrointestinal disorders (p=0.004 
      and p=0.02 respectively) and DRB1*01 with renal involvement (p=0.03) were found 
      in our patients. Patients carrying susceptible HLA-DRB1 alleles had a higher risk 
      for expression of cutaneous involvement (p=0.03), anti-coagulant antibody 
      development (p=0.01), and a lower risk for pulmonary disorders compared to 
      patients' negatives for susceptible alleles (p=0.04). Our findings on 
      associations between HLA risk allele (DRB1*03) as well as non-risk alleles with 
      particular clinical manifestations and between the potentially protective allele 
      (DRB1*01) and protection against renal involvement indicate the important role of 
      HLA class II genes in predisposing of specific serological and clinical features 
      of SLE disease which could be implicative for therapeutic applications and better 
      management of SLE patients.
FAU - Rasouli-Saravani, Ashkan
AU  - Rasouli-Saravani A
AD  - Department of Immunology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran. ashkan.rasouli90@gmail.com.
FAU - Tahamoli-Roudsari, Ahmad
AU  - Tahamoli-Roudsari A
AD  - Department of Internal Diseases Medicine, School of Medicine, Hamadan University 
      of Medical Sciences, Hamadan, Iran. tahamol_roudsari@yahoo.com.
FAU - Behzad, Mahdi
AU  - Behzad M
AD  - Department of Immunology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran. mhajibehzad@yahoo.com.
FAU - Hajilooi, Mehrdad
AU  - Hajilooi M
AD  - Department of Immunology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran. mhajilooi@gmail.com.
FAU - Solgi, Ghasem
AU  - Solgi G
AD  - Department of Immunology, School of Medicine, Hamadan University of Medical 
      Sciences, Hamadan, Iran AND Department of Dermatology, Psoriasis Research Center, 
      Farshchian Hospital, Hamadan University of Medical Sciences, Hamadan, Iran. 
      gh.solgi@umsha.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20210211
PL  - Iran
TA  - Iran J Allergy Asthma Immunol
JT  - Iranian journal of allergy, asthma, and immunology
JID - 101146178
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DRB1 Chains)
SB  - IM
MH  - *Alleles
MH  - Case-Control Studies
MH  - *Genetic Predisposition to Disease
MH  - HLA-DQ beta-Chains/*genetics
MH  - HLA-DRB1 Chains/*genetics
MH  - Haplotypes
MH  - Humans
MH  - Iran/epidemiology
MH  - Lupus Erythematosus, Systemic/*epidemiology/*etiology
MH  - Public Health Surveillance
OTO - NOTNLM
OT  - HLA-DQB1
OT  - HLA-DRB1 chains
OT  - Systemic lupus erythematosus
EDAT- 2021/02/28 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/02/27 21:15
PHST- 2020/09/03 00:00 [received]
PHST- 2020/12/03 00:00 [accepted]
PHST- 2021/02/27 21:15 [entrez]
PHST- 2021/02/28 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
AID - 10.18502/ijaai.v20i1.5413 [doi]
PST - epublish
SO  - Iran J Allergy Asthma Immunol. 2021 Feb 11;20(1):67-75. doi: 
      10.18502/ijaai.v20i1.5413.